FDA
-
-
-
-
-
-
-
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children
-
-
-
-
-
-
-
Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer
-
-
-
-
-
-
-
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
-
-
-
-
-
-
-
LogicBio Therapeutics Announces SUNRISE Phase 1/2 Clinical Design for LB-001 for the Treatment of Methylmalonic Acidemia in Pediatric Patients
-
-
-
-
-
-
-
LogicBio Reports Full Year 2019 Financial Results and Provides Business Updates
-
-
-
-
-
-
-
LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

